Basilea Stresses Derazantinib's FGFR Kinase Differentiation
Tumor Checkpoint Controller Also In Early Clinical Studies
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
